REXAHN PHARMACEUTICALS 10-K 12-31-2016

Company

Opus Genetics, Inc.

Filed

February 24, 2017

Period of Report

December 31, 2016

Accession Number

0001140361-17-009132

A 10-K is a company's comprehensive annual report, required by the SEC. It includes audited financial statements, a description of the business, risk factors, and management's discussion of results. Learn more about 10-K filings →